Connor, Clark & Lunn Investment Management (CC&L)’s Inovio Pharmaceuticals INO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,345	Closed	-$49K	–	1315
2022 Q3	$49K	Buy	+2,345	New	+$60K	﹤0.01%	1067
2018 Q4	–	Sell	-7,222	Closed	-$482K	–	992
2018 Q3	$482K	Sell	7,222 -1,213	-14%	-$67.5K	﹤0.01%	710
2018 Q2	$397K	Buy	8,435 +2,818	+50%	+$155K	﹤0.01%	817
2018 Q1	$317K	Buy	+5,617	New	+$304K	﹤0.01%	613
2016 Q1	–	Sell	-2,367	Closed	-$191K	–	867
2015 Q4	$191K	Buy	+2,367	New	+$188K	﹤0.01%	708

Other funds holding INO

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s INO Position: Q4 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Inovio Pharmaceuticals (INO) in Q4 2022, closing a stake of 2,345 shares — an estimated $49K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in INO in Q4 2015 and held it in 5 quarters. The position peaked at $482K in Q3 2018. 183 funds tracked by Wall St. Rank hold INO as of Q4 2022.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Inovio Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 2,345 Inovio Pharmaceuticals shares in Q4 2022, an estimated $49K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Inovio Pharmaceuticals in Q4 2015 and held it in 5 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Inovio Pharmaceuticals position peaked at $482K in Q3 2018.
183 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2022, filed 10 Feb 2023.